Acne Mechanisms, Severity Descriptions, and Cosmetic Decisions

Acne Vulgaris Pathophysiology

Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit affecting more than 85% of adolescents and a rising proportion of adult women. In advanced clinical practice, successful treatment depends on mastering the four interdependent biological pillars governing follicular obstruction, microbial colonization, and tissue destruction.

The Four Etiologic Pillars

1. Follicular Retention Hyperkeratinization

Normal follicular infundibula shed single corneocytes that travel to the surface within the sebum stream. In acne-prone individuals, infundibular keratinocytes proliferate excessively and exhibit abnormal intercellular adhesion. Altered differentiation, adhesion, inflammation, and sebum composition can contribute to a cohesive cellular impaction that occludes the follicular ostium.

2. Androgen-Mediated Sebum Hypersecretion

Sebaceous glands are highly responsive to circulating androgens. Free testosterone and dehydroepiandrosterone sulfate (DHEA-S) enter sebocytes, where the enzyme 5-alpha reductase (predominantly type 1 in cutaneous tissue) converts testosterone into 5-alpha-dihydrotestosterone (DHT). DHT binds to intracellular androgen receptors with high affinity, stimulating sebocyte proliferation and profuse sebum production rich in squalene, wax esters, and triglycerides.

3. Microbial Proliferation (Cutibacterium acnes)

Follicular occlusion creates an anaerobic, lipid-dense canal. This environment favors interactions involving Cutibacterium acnes (formerly Propionibacterium acnes), an aerotolerant, gram-positive anaerobic rod resident in the pilosebaceous unit. C. acnes secretes lipases that hydrolyze sebum triglycerides into irritating free fatty acids, accelerating comedogenesis.

4. Perifollicular Inflammatory Cascade

C. acnes activates Toll-like Receptor 2 (TLR-2) on perifollicular macrophages and keratinocytes. This triggers nuclear factor kappa B (NF-κB), stimulating pro-inflammatory cytokine release:

• Interleukin-1 alpha (IL-1α): Promotes infundibular hyperkeratinization.
• Interleukin-8 (IL-8): A signal promoting neutrophil recruitment. Interleukin-12 (IL-12) contributes to cell-mediated immune responses; it is not interchangeable with IL-8 as a neutrophil chemotactic signal.
• Tumor Necrosis Factor-alpha (TNF-α): Increases microvascular permeability.

Recruited neutrophils release matrix metalloproteinases (MMPs) and reactive oxygen species (ROS) that degrade the follicular wall. When the wall ruptures, lipids, keratin, and antigens extravasate into the dermis, converting a microscopic impaction into an intense inflammatory reaction.

Progression of Follicular Lesions

1. Microcomedo: The subclinical, microscopic precursor impaction.
2. Closed Comedo (Whitehead): An elevated, non-inflammatory papule (1–3 mm) with an intact, microscopic follicular ostium trapping unoxidized sebum and keratin.
3. Open Comedo (Blackhead): A non-inflammatory lesion with a dilated orifice. The dark plug results from melanin oxidation and compacted lipids upon air contact, not trapped dirt.
4. Inflammatory Papule: A tender, erythematous elevation (< 5 mm) resulting from partial follicular rupture and dermal infiltration.
5. Pustule: A superficial lesion filled with purulent exudate and necrotic neutrophils.
6. Nodule & Pseudocyst: Deep follicular rupture into the reticular dermis. Nodules are firm, painful masses (> 5 mm); pseudocysts are fluctuant inflammatory cavities lacking epithelial linings. Both carry severe scarring risk.

Severity descriptions and role boundaries

Educational four-grade systems often progress from mainly comedonal findings through increasing inflammation to deep nodular or cyst-like disease. Clinical severity systems vary, so a grade number is meaningful only within the named framework. Do not diagnose the entire condition from one count or assume every client in a grade should receive the same peel.

Record the observed mix of comedones, inflamed lesions, depth, distribution, pain, and reported scarring. Significant inflammation, painful deep lesions, rapid worsening, or scarring warrants medical assessment. The cosmetic role should support appropriate care rather than promise to cure disease.

Variants described in medical literature

• Acne Cosmetica: Low-grade closed comedones associated with some cosmetic formulations in susceptible clients. Ingredient names alone do not provide a universal comedogenicity prediction.
• Acne Mechanica: Flare-ups triggered by heat, pressure, and friction from equipment (e.g., sports helmets, straps, facial masks).
• Acne Excoriée: Compulsive picking and scratching of minor or imagined blemishes, leaving crusts, linear excoriations, and scars.

Extraction choices

Only suitable superficial noninflamed impactions are candidates for trained cosmetic extraction. Avoid inflamed pustules, deep lesions, open skin, and unexplained bumps. Do not puncture or squeeze a lesion to establish what it contains. Stop when material does not release easily, or when pain, bruising, or bleeding occurs.

Virginia scope and sanitation apply regardless of severity terminology. A theory reference to a lancet does not establish legal authority for incision or drainage. Use only a lawful suitable method and refer targets needing medical evaluation.

Medicines, barrier tolerance, and medical coordination

Acne care may include benzoyl peroxide, topical retinoids, antibiotics, hormonal approaches, or isotretinoin under appropriate medical guidance. These have different mechanisms and precautions. Record actual use and ask about irritation. The esthetician should not prescribe or independently stop treatment to qualify a client for a peel.

Current isotretinoin labeling and patient guidance warn against waxing and skin-resurfacing procedures during treatment and for at least six months afterward. Do not replace that warning with a universal six-to-twelve-month legal ban on every procedure, or assume a softer abrasive bypasses it. Obtain appropriate provider guidance for the actual requested service.

Recent topical actives and other procedures can reduce tolerance. There is no universal three-to-five-day washout that establishes safety for every prescription, product, or client. Coordinate changes with the prescriber and follow device/product restrictions. Persistent irritation warrants deferral and appropriate care.

A client with painful inflammatory lesions asks for 20% TCA soon after isotretinoin. The request has multiple problems: current skin suitability, medication precautions, and Virginia's explicit requirement that TCA be less than 20%. Do not offer LED or extraction as an automatic treatment for the medical problem. Refer for appropriate acne care, then reassess any later lawful cosmetic service.

Home guidance should favor a compatible gentle routine, realistic expectations, and avoiding picking or repeated aggressive exfoliation. Sun protection supports care but does not erase an injured barrier. Document observed condition, service exclusions, medicines reported, and referral. On the exam, distinguish acne pathogenesis from the choice to perform a procedure; knowing a mechanism does not establish that a particular client is suitable.

Sources and current rules

Virginia exfoliators; AAD isotretinoin guidance. Checked October 7, 2026.

Experimental TLR2 and acne cytokine study. Checked October 7, 2026.